Kelly Olino, MD, FACS
Associate Professor TermCards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Leader, Skin Cancer Surgery, Melanoma Program
Clinical Director of the Smilow Melanoma Program, Yale Cancer Center
Co-Director Cutaneous Malignancy Tumor Board, Yale Cancer Center
Medical Student Clerkship Liaison for Division of Surgical Oncology, Surgery
Chair Credentials Committee and Secretary of Medical Staff, Surgery
Contact Info
Surgical Oncology
310 Cedar Street, FMB130
New Haven, CT 06520
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Leader, Skin Cancer Surgery, Melanoma Program
Clinical Director of the Smilow Melanoma Program, Yale Cancer Center
Co-Director Cutaneous Malignancy Tumor Board, Yale Cancer Center
Medical Student Clerkship Liaison for Division of Surgical Oncology, Surgery
Chair Credentials Committee and Secretary of Medical Staff, Surgery
Contact Info
Surgical Oncology
310 Cedar Street, FMB130
New Haven, CT 06520
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Leader, Skin Cancer Surgery, Melanoma Program
Clinical Director of the Smilow Melanoma Program, Yale Cancer Center
Co-Director Cutaneous Malignancy Tumor Board, Yale Cancer Center
Medical Student Clerkship Liaison for Division of Surgical Oncology, Surgery
Chair Credentials Committee and Secretary of Medical Staff, Surgery
Contact Info
Surgical Oncology
310 Cedar Street, FMB130
New Haven, CT 06520
United States
About
Copy Link
Titles
Associate Professor Term
Leader, Skin Cancer Surgery, Melanoma Program; Clinical Director of the Smilow Melanoma Program, Yale Cancer Center; Co-Director Cutaneous Malignancy Tumor Board, Yale Cancer Center; Medical Student Clerkship Liaison for Division of Surgical Oncology, Surgery; Chair Credentials Committee and Secretary of Medical Staff, Surgery
Biography
Kelly Olino, MD, FACS, is a doubly board -certified surgeon who provides patients with comprehensive surgical care including resection of skin and soft tissue tumors including melanoma, merkel cell carcinoma, sarcoma, and advanced cutaneous squamous cell and basal cell carcinoma, including minimally invasive techniques for metastatic disease. Dr. Olino is a past recipient of the Society for Surgical Oncology’s Clinical Investigator Award to support her research in tumor immunology. She continues this work at Yale and has been funded through the Calabresi Immune-Oncology scholar program and the Skin Cancer SPORE career enhancement program. She continues her work in translational research combining her knowledge of tumor immunology with her clinical acumen. She currently serves on the NCCN non-melanoma cutaneous malignancy committee.
Appointments
Surgical Oncology
Associate Professor on TermPrimary
Other Departments & Organizations
- Cancer Immunology
- Sarcoma Program
- Skin & Kidney Cancer Program
- Surgery
- Surgical Oncology
- Yale Cancer Center
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Fellowship
- The Memorial Sloan Kettering Cancer Center (2015)
- Residency
- The Johns Hopkins Hospital (2013)
- MD
- The Johns Hopkins School of Medicine (2005)
- BS
- Cornell University, Biological Sciences-Neurobiology (2000)
Research
Copy Link
Overview
Tumor immunology
Medical Research Interests
ORCID
0000-0001-6209-5218
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Harriet Kluger, MD
James Clune, MD
Sajid A Khan, MD, FACS, FSSO
Stephan Ariyan, MD, MBA
Thuy Tran, MD, PhD
Jeffrey Ishizuka, MD, DPhil
Melanoma
Immunotherapy
Carcinoma, Merkel Cell
Adrenocortical Carcinoma
Carcinoma, Squamous Cell
Publications
2026
A risk stratification schema for patients with non–small cell lung cancer with multiple organ metastases.
Esnaola G, Wang M, Resio B, Pan A, Lee D, Cohen A, Kaur M, Schmitter M, Ishizuka J, Olino K. A risk stratification schema for patients with non–small cell lung cancer with multiple organ metastases. Journal Of Clinical Oncology 2026, 44: 11138-11138. DOI: 10.1200/jco.2026.44.16_suppl.11138.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPattern of metastasisSite of metastasisCell lung cancerMultiple organ sitesMetastatic sitesTargeted therapySystemic therapyPrognostic valueLung cancerMetastatic non-small cell lung cancerOrgan sites of metastasesTime to next therapyResponse to systemic therapyClustering of metastasesIndividual organ sitesMultiple organ metastasesReal-world patternsKaplan Meier methodSite of diseaseDatabase of patientsRisk stratification schemaPoor overall survivalInclusion of patientsEGFR mutationsDrivers of organotropism and patterns of metastatic progression in metastatic non–small cell lung cancer.
Esnaola G, Resio B, Pan A, Lee D, Cohen A, Wang M, Schmitter M, Ishizuka J, Olino K. Drivers of organotropism and patterns of metastatic progression in metastatic non–small cell lung cancer. Journal Of Clinical Oncology 2026, 44: e20541-e20541. DOI: 10.1200/jco.2026.44.16_suppl.e20541.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerReal-world overall survivalCell lung cancerOrgan sitesSystemic therapyPrognostic valueMetastatic progressionAdvanced non-small cell lung cancerFollow-upLung cancerMedian real-world overall survivalMetastatic non-small cell lung cancerMetastatic potentialOrgan-specific spreadPattern of metastasisDistant lymph nodesKaplan Meier methodDistant organ sitesDistribution of metastasesPhenotype of patientsInterferon-gamma responsesSite-specific diseaseClinico-genomic databaseMetastatic diagnosisOverall survivalEx vivo expansion of melanoma tumor infiltrating lymphocytes leads to a dominant exhausted T cell population with lack of memory markers
Coppola G, Kerr S, Cha P, Bersenev A, Olino K, Kluger H, Sznol M, Weiss S, Bosenberg M, Kleinstein S, Krause D, Hurwitz M, Katz S. Ex vivo expansion of melanoma tumor infiltrating lymphocytes leads to a dominant exhausted T cell population with lack of memory markers. Cancer Immunology Research 2026, 14: 861-874. PMID: 41686210, PMCID: PMC13032746, DOI: 10.1158/2326-6066.cir-25-0798.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTumor-infiltrating lymphocytesMemory cell phenotypeEx vivo expansionInfiltrating lymphocytesEx vivoPatient tumorsT cellsEfficacy of tumor-infiltrating lymphocytesSubpopulations of tumor-infiltrating lymphocytesMelanoma tumor-infiltrating lymphocytesTIL expansionCD8 T cellsCell phenotypeT cell populationsReceptor PD1Individual clonotypesDN cellsEx vivo growthPost-expansionTCR sequencesClinical trialsFDA approvalStem-likeCell differentiation stateTherapeutic effect
2025
Lipophilic statins deplete GPX4 to promote ferroptosis and sensitize cancer cells to immune checkpoint blockade
Talty R, Brooks V, McGeary M, Milette S, Zheng S, Flem-Karlsen K, Daniels A, Deshmukh M, Park K, Caraccio W, Yan H, Echeandia-Francis C, McNamara M, Hong S, Kirwin D, Olino K, Johnson C, Bosenberg M, Micevic G, Roy S. Lipophilic statins deplete GPX4 to promote ferroptosis and sensitize cancer cells to immune checkpoint blockade. Molecular Cancer Therapeutics 2025, 25: 759-770. PMID: 41423587, PMCID: PMC12752129, DOI: 10.1158/1535-7163.mct-25-0667.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLipophilic statinsCD8+ T cell infiltrationCell deathPatient-derived melanoma cell linesAnticancer effectsAnticancer effects of statinsImmune checkpoint blockadeTherapeutic potentialT cell infiltrationEffects of statinsMelanoma cell linesFeatures of ferroptosisCheckpoint blockadeAntitumor immunityTumor clearanceOverall survivalStatin useColorectal cancerStatin-induced cell deathStatinsCancer typesSimvastatinCell linesMelanomaFerroptosisUse of imiquimod topical therapy for management of malignant melanoma positive margins
Lewis K, Islam S, Alper D, Carney M, Choi J, Leventhal J, Ariyan S, Baumann R, Olino K, Clune J. Use of imiquimod topical therapy for management of malignant melanoma positive margins. Frontiers In Oncology 2025, 15: 1666463. PMID: 41234721, PMCID: PMC12605384, DOI: 10.3389/fonc.2025.1666463.Peer-Reviewed Original ResearchThis study investigates the effectiveness of 5% topical imiquimod therapy as a safe, cost-effective alternative to surgery for managing positive melanoma margins, achieving an 84% clinical response rate.Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma
Frey A, Clulo K, Fei Y, Dumit T, Scallo F, Allen J, Chang E, Perry C, Wirth L, Jacobs D, Braun D, Bosenberg M, Tran T, Clune J, Kluger H, Olino K, Ishizuka J. Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma. Cell Reports 2025, 44: 116359. PMID: 41042672, PMCID: PMC12646823, DOI: 10.1016/j.celrep.2025.116359.Peer-Reviewed Original ResearchThis study investigates an IL-7-enhanced mRNA vaccine targeting virus-associated Merkel cell carcinoma, showing durable immune responses in mouse models and patient samples, addressing cancer recurrence challenges.Case Report: Complete response to pembrolizumab monotherapy in a geriatric patient with metastatic Merkel cell carcinoma and TNBC
Liu J, Olino K, Lustberg M, Kanowitz J. Case Report: Complete response to pembrolizumab monotherapy in a geriatric patient with metastatic Merkel cell carcinoma and TNBC. Frontiers In Oncology 2025, 15: 1579287. PMID: 40936701, PMCID: PMC12420252, DOI: 10.3389/fonc.2025.1579287.Peer-Reviewed Case Reports and Technical NotesConceptsMetastatic Merkel cell carcinomaTriple-negative breast cancerMerkel cell carcinomaPembrolizumab monotherapyCell carcinomaPoor prognosisBreast cancerLocally advanced triple-negative breast cancerMetastatic MCCClinical managementAggressive neuroendocrine skin cancerGeriatric patientsAnti-PD-1Efficacy of pembrolizumabNeuroendocrine skin cancerAdvanced cutaneous malignanciesCutaneous malignanciesOlder adult patientsTraditional chemotherapyPatient selectionAdult patientsAdvanced skinClinical trialsSkin cancerPatientsTwenty‐five years without progress: The enduring challenge of soft tissue sarcomas
Hardy N, Frej K, Nkansah R, Olino K, Deshpande H, Ma X, Trent J, Costa P. Twenty‐five years without progress: The enduring challenge of soft tissue sarcomas. Cancer 2025, 131: e35906. PMID: 40396557, DOI: 10.1002/cncr.35906.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSoft tissue sarcomasMedian survivalTissue sarcomasDistant diseaseNo significant differenceImproved survivalSurvival improvementPoor prognosisBreast cancerLung cancerRare diseaseLack of commercial interestSurvival rateSignificant differenceCancerSurvivalNovel drugsPositive drugDiseaseSarcomaPatientsTwenty-fiveBiological mechanismsMonthsDrugEfficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma
Grover P, Lo S, Li I, Kuijpers A, Kreidieh F, Williamson A, Amaral T, Dimitriou F, Placzke J, Olino K, Vitale M, Saiag P, Gutzmer R, Allayous C, Bagge R, Mattsson J, Asher N, Carter T, Meniawy T, Lawless A, Czapla J, Warburton L, Gaudy-Marqueste C, Grob J, Collins R, Zhang E, Kessels J, Neyns B, Mehmi I, Hamid O, Julve M, Furness A, Margolin K, Lev-Ari S, Ressler J, Haque W, Khattak M, Wicky A, Roberts-Thomson R, Arance A, Warrier G, Schollenberger M, Parente P, Chatziioannou E, Lipson E, Michielin O, Weber J, Hoeller C, Larkin J, Atkins M, Essner R, Johnson D, Sullivan R, Nathan P, Schachter J, Lebbe C, Ascierto P, Kluger H, Rutkowski P, Dummer R, Garbe C, Lorigan P, Burton E, Tawbi H, Haanen J, Carlino M, Menzies A, Long G. Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma. Annals Of Oncology 2025, 36: 807-818. PMID: 40204154, DOI: 10.1016/j.annonc.2025.03.021.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleHumansImidazolesImmune Checkpoint InhibitorsMaleMelanomaMiddle AgedNeoplasm StagingNivolumabOximesProgrammed Cell Death 1 ReceptorPyridonesPyrimidinonesRetrospective StudiesSkin NeoplasmsConceptsDistant metastasis-free survivalAnti-PD-1Recurrence-free survivalStage IIIA melanomaRisk of recurrenceAssociated with higher riskFollow-upAdjuvant therapyAmerican Joint Committee on Cancer eighth editionAssociated with higher risk of recurrenceAnti-PD-1 groupClinical trialsEfficacy of adjuvant therapyHigh risk of recurrenceAdjuvant targeted therapyMedian Follow-UpMetastasis-free survivalHigher Breslow thicknessProspective randomised trialAdjuvant drug therapyHigher mitotic rateAdjuvant pembrolizumabBreslow thicknessAdjuvant treatmentCutaneous melanomaReal-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma
Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.Peer-Reviewed Original ResearchCitationsConceptsMerkel cell carcinomaMerkel cell carcinoma casesT-VECCell carcinomaMedian numberAnti-PD-1 blockadeStage IIIB-IV melanomaAdvanced Merkel cell carcinomaIn-Transit MelanomaIn-transit diseaseICI therapyTalimogene laherparepvecAdvanced melanomaCancer immunotherapyMetastatic sitesPartial responseIn-transitRegional metastasesMedian ageGrade 3Adverse eventsTreatment cyclesDisease progressionMelanomaPatients
Clinical Trials
Current Trials
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)
IRB ID2000035965RoleSub InvestigatorPrimary Completion Date04/21/2027Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Copy Link
Activities
activity The Society of Surgical Oncology
03/01/2022 - PresentProfessional OrganizationsProgram CommitteeDetailsScientific Program Committee- Chair Immuno-oncology subgroupactivity Association for Academic Surgery
2016 - PresentProfessional OrganizationsProgram Committeeactivity Schwartz Cancer Center Grand Rounds Planning Committee
2021 - PresentCommitteesCommittee Memberactivity Yale New Haven Hospital Credentials Committee
09/01/2021 - PresentCommitteesMemberactivity Status of Women in Medicine- Department of Surgery Liason
2022 - PresentCommitteesLiaison
Honors
honor Texas Rising Stars
01/01/2018Regional AwardSuper DoctorsDetailsUnited Stateshonor Golden Scalpel Medical Student Teaching Award
05/20/2016Other AwardUniversity of Texas Medical Branch School of MedicineDetailsUnited Stateshonor Society for Surgical Oncology Clinical Investigators Award
04/01/2016National AwardSociety for Surgical Oncology FoundationDetailsUnited Stateshonor Frank Coulson Resident Clinical Excellence Award
06/22/2013Other AwardThe Johns Hopkins School of MedicineDetailsUnited Stateshonor Department of Surgery Medical Student Teaching Award
06/22/2013Other AwardThe Johns Hopkins School of MedicineDetailsUnited States
Clinical Care
Copy Link
Are You a Patient?
Please visit the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileRelated Yale Medicine Content
17 Condition Fact Sheets5 Clinical Departments1 Clinical Trial10 News ArticlesSee All Related Content on Yale Medicine
Overview
Kelly Olino, MD, is a surgical oncologist with additional training in cancer immunotherapy. She treats skin cancer in patients who range from teenagers to people in their 90s. “I see a wide variety of people, because skin cancer affects everybody, unfortunately,” she says.
As a surgeon, Dr. Olino cares for patients in the office and in the operating room, removing skin and soft tissue tumors that occur anywhere on the body, and performing minimally invasive surgeries to treat metastatic skin cancer when it spreads to internal organs. “When I am treating a patient with skin cancer, I think not only about the technical expertise required to perform a given surgery, but more importantly how the surgery fits into the scope of a larger plan for that patient,” says Dr. Olino, who has additional training in immunotherapy, which she describes as a “revolutionary” step in the treatment of skin cancer. Skin cancer specialists were among the first doctors to successfully use immunotherapy, which harnesses the body’s own immune system to target cancer.
Dr. Olino decided to become a surgical oncologist partly because the patients she met as a trainee were so appreciative. She, in turn, has always taken the time to make sure each patient fully understands his or her condition and treatment. “Patients should know what's going on. Their families should know. I joke with them all the time. I say to them, "You know, I'm bilingual. I speak “Doctor” and I speak English, so please let me know if I start to speak “Doctor,” because if you don’t understand what I’m doing and why, it's time for me to explain it again.”
As an assistant professor of surgery at Yale School of Medicine, Dr. Olino focuses her research on immunotherapy for skin cancer. She is currently part of a team that is looking at novel ways to combine different types of immunotherapies and move those therapies from the laboratory to patient care clinics.
Clinical Specialties
Fact Sheets
Merkel Cell Carcinoma (MCC)
Learn More on Yale MedicineSoft Tissue Sarcomas
Learn More on Yale MedicineDiagnosing Pediatric Sarcomas
Learn More on Yale MedicineSentinel Lymph Node Biopsy
Learn More on Yale Medicine
Board Certifications
Complex General Surgical Oncology
- Certification Organization
- AB of Surgery
- Original Certification Date
- 2016
Yale Medicine News
News & Links
Copy Link
Media
Together Against Melanoma: An Educational Symposium for Patients and Caregivers
May 12, 2026
Welcome: Kelly Olino, MD, FACS
Speakers: Jonathan Leventhal, MD, Kelly Olino, MD, FACS, Thuy Tran, MD, PhD, Jeffrey Ishizuka, MD, PhD
Panelists: Carla Beccera, PA; Lisa Fox, APRN, MSN; Sajid Khan, MD; David Schoenfeld, MD, PhD; Tormod Westvik, MD
Smilow Shares CME: Neoadjuvant Therapy and Cutaneous Malignancy
Presentations by:
Aarti Bhatia, MD, MPH
Associate Professor of Medicine (Medical Oncology); Clinical Research Team Leader, Head and Neck Cancers Program
Kelly Olino, MD, FACS
Assistant Professor of Surgery (Oncology); Leader, Skin Cancer Surgery, Melanoma Program; Clinical Director of the Smilow Melanoma Program, Yale Cancer Center; Co-Director Cutaneous Malignancy Tumor Board, Yale Cancer Center; Medical Student Clerkship Liaison for Division of Surgical...
Ansley Roche, MD, BA
Assistant Professor of Surgery (Otolaryngology)
Kathleen Cook Suozzi, MD
Associate Professor Term
Thuy Tran, MD, PhD
Assistant Professor of Medicine (Medical Oncology)
Nomograms and Gene Expression Profiles for Cutaneous Malignancies
Presenters:
Aarti Bhatia, MD, MPH
Sean Christensen, MD, PhD
Kelly Olino, MD
Ansley Roche, MD
Kathleen Suozzi, MD
Thuy Tran, MD, PhD
News
- May 28, 2026
Yale Surgery Announces 2026 Transformational Educators Honor Roll
- May 13, 2026
Together Against Melanoma: An Educational Symposium for Patients and Caregivers
- October 28, 2025
Yale Develops Dual-Action Vaccine to Combat Aggressive Merkel Cell Carcinoma
- May 22, 2025
Defying the Odds: A WWII Veteran’s Journey with Melanoma
Get In Touch
Copy Link
Contacts
Surgical Oncology
310 Cedar Street, FMB130
New Haven, CT 06520
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.